The

After GlaxoSmithKline’s diabetes drug Avandia was linked to heart disease in May 2007, a fierce debate ensued, with much of it played out in scholarly journals. Just who wrote all those articles? That’s what the Mayo Clinic wanted to find out. Now, researchers have analyzed more than 200 articles that…

Losing Ratiopharm to Teva Pharmaceutical Industries may have made Pfizer a winner. That’s the theory advanced by Motley Fool , which says that to outbid Teva, Pfizer would have had to overpay. And overpaying, as anyone knows, is losing. Here’s the rationale: Teva could pay about $5 billion for the…

The next time we meet, healthcare reform may have survived the U.S. House–or gone down in flames. A vote is now expected Sunday on the sweeping overhaul plan, which is designed to cover nearly all of

AstraZeneca has prevailed: The first jury to hear a Seroquel case decided that the warnings on its label were adequate, so patients and doctors should have had enough information about the drug’s risks. “The jury determined… that the information in the Seroquel label provided prescribing doctors an adequate warning with…

Will

FTC Chairman Jon Leibowitz says the need for legislation prohibiting illegal pay-for-delay settlements remains–even though a ban on such deals has been dropped from the healthcare reform bill . “President Obama is strongly behind a legislative provision banning anticompetitive settlements between branded and generic drug companies, and there is growing…

Pfizer agreed to drop an 8-year-old patent infringement lawsuit against Eli Lilly over Viagra after a U.S. government agency rejected part of the male impotence drug’s patent. Report

Original Source of Pfizer abandons Viagra suit against Lilly

The folks at GlaxoSmithKline must be celebrating today: Rival Novartis has handed back U.S. rights to a drug that might have become a copycat version of the GSK blockbuster Advair. That move gives Glaxo one less problem to worry about. GSK chief Andrew Witty has been pooh-poohing the potential of…

Why do Americans pay so much for their pharmaceuticals? That’s the question posed by Sen. Herb Kohl, a Democrat and chairman of the Senate Special Committee on Aging, who has written to the world’s top drugmakers to demand an explanation. “Americans pay, on average, twice as much as people in…